Sales & Marketing News | pharmaphorum

News

Lilly says Foundayo safety confirmed in ACHIEVE-4 trial

Eli Lilly's ACHIEVE-4 trial results for oral GLP-1 Foundayo set up a filing in diabetes, and provide safety data sought by the FDA.

News

Daiichi exits OTC, with $1.55bn unit sale to Suntory

Daiichi Sankyo has agreed to sell its consumer health unit to food and beverage giant Suntory, following a well-trodden path for big pharma companies.

News

FDA seeks safety data for Lilly's oral GLP-1 Foundayo

The FDA has laid out post-marketing safety testing requirements for Lilly's weight-loss pill Foundayo, including clinical trials.

News

Novo Nordisk partners OpenAI on R&D "transformation"

Seeking an R&D edge, Novo Nordisk has become the latest big pharma group to forge an alliance with tech giant OpenAI.

News

Travere claims first FDA OK in rare kidney disease FSGS

Shrugging off an earlier phase 3 disappointment, Travere’s Filspari has become the first FDA-approved treatment for rare kidney disease FSGS.

News

FDA hands another rejection to Replimune's melanoma therapy

Replimune has had its advanced melanoma treatment RP1 turned down by the FDA for a second time, prompting job losses.

Lilly says Foundayo safety confirmed in ACHIEVE-4 trial

Daiichi exits OTC, with $1.55bn unit sale to Suntory

FDA seeks safety data for Lilly's oral GLP-1 Foundayo

Novo Nordisk partners OpenAI on R&D "transformation"

Travere claims first FDA OK in rare kidney disease FSGS

FDA hands another rejection to Replimune's melanoma therapy

FDA hands BeOne, Taiho approvals for blood cancers

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks